North Shore Therapeutics
Developer of evidence-based digital therapeutics for serious mental illnesses, focused on mobile and augmented-reality interventions to address negative symptoms of schizophrenia. The company conducts early-phase clinical studies, publishes trial results, and frames its development within FDA "software as a medical device" pathways.
Industries
Nr. of Employees
small (1-50)
North Shore Therapeutics
Products
Augmented-reality therapeutic application for negative symptoms of schizophrenia
An AR-based mobile therapeutic designed to activate reward circuitry and deliver gamified cognitive/behavioral activities aimed at reducing negative symptoms and defeatist beliefs.
NST-SPARK
Therapeutic Augmented Reality application for managing negative symptoms of schizophrenia, activating reward circuitry to drive engagement and durable therapeutic outcomes.
Augmented-reality therapeutic application for negative symptoms of schizophrenia
An AR-based mobile therapeutic designed to activate reward circuitry and deliver gamified cognitive/behavioral activities aimed at reducing negative symptoms and defeatist beliefs.
NST-SPARK
Therapeutic Augmented Reality application for managing negative symptoms of schizophrenia, activating reward circuitry to drive engagement and durable therapeutic outcomes.
Services
Design and execution of early-phase (feasibility/Phase 1B) studies to assess engagement, acceptability, and preliminary outcomes of mobile/AR therapeutic interventions.
Design and execution of early-phase (feasibility/Phase 1B) studies to assess engagement, acceptability, and preliminary outcomes of mobile/AR therapeutic interventions.
Expertise Areas
- Digital therapeutics development
- Augmented reality therapy for psychiatry
- Clinical trial management for digital interventions
- Behavioral intervention and gamification design
Key Technologies
- Augmented reality (AR)
- Mobile health applications (mHealth)
- Gamification
- Software-as-a-medical-device (SaMD)
News & Updates
Preprint describing methods and outcomes from a Phase 1B feasibility study of an AR therapeutic for negative symptoms of schizophrenia.
Completed a Phase 1B study (September 2024) assessing feasibility, engagement, and preliminary outcomes of an AR-based therapeutic for negative symptoms of schizophrenia; results showed high engagement and progress toward life goals among participants.
Preprint describing methods and outcomes from a Phase 1B feasibility study of an AR therapeutic for negative symptoms of schizophrenia.
Completed a Phase 1B study (September 2024) assessing feasibility, engagement, and preliminary outcomes of an AR-based therapeutic for negative symptoms of schizophrenia; results showed high engagement and progress toward life goals among participants.